Major prevalence of cancer and rising awareness regarding advanced cancer treatments are some of the key factors driving market revenue growth
The global T-cell therapy market size is expected to reach USD 21 Billion in 2028 and register a CAGR of 20.4% over the forecast period, according to the latest report by Reports and Data. Key factors such as increasing geriatric population globally, rising awareness about advanced cancer treatments, and major prevalence of cancers are driving market revenue growth. T-cell therapy is a type of immunotherapy that involves genetic modification of T-cells. This process is used to treat different types of cancers.
There are mainly three main types of T-cell therapies; CAR T-cell therapy, T-cell receptor (TCR)-based, and tumor infiltrating lymphocytes (TIL)-based. CAR T-cell therapy or Chimeric Antigen Receptor T-cell therapy is one of the most effective methods of cancer treatment. CAR T-cell therapy segment accounted for majority revenue share in the global market in 2020. This can be attributed to increasing number of clinical trials for CAR T-cell therapy and increasing investment in research related to CAR T-cell therapy.
Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2508
The report puts an emphasis on the information regarding the key players with a special focus on their company profile, business overview, recent advancements, product catalog, and strategic business plans. It provides a comprehensive overview of the strategic alliances in the market under taken by the key players such as mergers and acquisitions, joint ventures, collaborations, partnerships, agreements, product launches, brand promotions, and corporate deals, among others.
Key companies operating in the market and profiled in the report include:
Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, and Celgene Corporation.
Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2508
The T-Cell Therapy market takes into account major geographical locations such as North America, Europe, Asia Pacific, Latin America, and Middle East Africa to offer key insights into market growth, market size, market share, revenue growth, current and emerging trends, supply and demand ratio, import/export, consumer demand and behavior, and presence of key players in each region. The report offers an in-depth country wise analysis to impart better understanding of the market and its growth prospects.
Segments Covered in the report
Modality Outlook (Revenue, USD Billion; 2018-2028)
- Research
- Commercialized
Therapy Outlook (Revenue, USD Billion; 2018-2028)
- CAR T-cell therapy
- T-cell receptor (TCR)-based
- Tumor infiltrating lymphocytes (TIL)-based
Indication Outlook (Revenue, USD Billion; 2018-2028)
- Hematologic Malignancies
- Lymphoma
- Myeloma
- Leukemia
- Solid Tumors
- Brain Central Nervous System
- Liver Cancer
- Melanoma
- Others
Key Regions Analyzed in the Report include:
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- Italy
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East Africa
- Saudi Arabia
- U.A.E.
- South Africa
- Rest of MEA
To know more about the report @ https://www.reportsanddata.com/report-detail/t-cell-therapy-market
Furthermore, it consists information about individual segment of the T-Cell Therapy market based on the types and application. The report also offers insights about the key segments expected to register significant revenue growth over the forecast period and primary trends influencing their growth. It also offers CAGR and market share values for each segment to provide clear understanding of demand and trend in the global market.
Some Key Highlights from the Report:
- In January 2021, OrganaBio launched a new cell product, ImmunoPAC-T-CB T cells. These cells are obtained from full-term umbilical cord blood taken from donors that supports allogeneic immune cell-based therapy development.
- Research segment accounted for largest revenue share in the global market in 2020. This can be attributed to rising focus on research of T-cell therapy, and increasing investment in cell therapy-based clinical research and development activities.
Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/2508
Thank you for reading our report. For any specific details on customization of this report, please get in touch with us. We will ensure the report you get is well-suited to your needs.
Browse More Reports:
Halitosis Treatment Market @ https://www.reportsanddata.com/report-detail/halitosis-treatment-market
In vivo CRO Market @ https://www.reportsanddata.com/report-detail/in-vivo-cro-market
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John W
Head of Business Development
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
